Dominic Piscitelli - 02 Jan 2024 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
Chief Financial Officer
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
02 Jan 2024
Transactions value $
$0
Form type
4
Filing time
03 Jan 2024, 16:18:59 UTC
Previous filing
19 Dec 2023
Next filing
17 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Award $0 +180K $0.00 180K 02 Jan 2024 Common Stock 180K $9.14 Direct F1
transaction ORIC Restricted Stock Unit Award $0 +30K $0.00 30K 02 Jan 2024 Common Stock 30K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
F3 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.